Expertise in
22
conditions

Dr. Daniel J. Wallace

Rheumatology
Cedars-Sinai Rheumatology-Los Angeles
8723 Alden Dr Ste 250, 
Los Angeles, CA 
Accepting New Patients
Referral may be required
Before you request
Expertise in
22
conditions
Cedars-Sinai Rheumatology-Los Angeles
8723 Alden Dr Ste 250, 
Los Angeles, CA 

Overview

Daniel Wallace is a Rheumatologist practicing medicine in Los Angeles, California.

Dr. Wallace is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Sjogren Syndrome, and Rheumatoid Arthritis (RA).

He is actively involved in clinical research, co-authoring 249 peer reviewed articles and participating in 11 clinical trials. Dr. Wallace is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HealthPartners
  • POS
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

Cedars-Sinai Rheumatology-Los Angeles
8723 Alden Dr Ste 250, Los Angeles, CA 90048
Other Locations
Daniel J. Wallace M D A Medical Corp.
8750 Wilshire Blvd Ste 210, Beverly Hills, CA 90211

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus
Enrollment Status: Completed
Publish Date: August 24, 2026
Intervention Type: Drug
Study Drugs: Low Dose Mesenchymal Stem Cells, High Dose Mesenchymal Stem Cells
Study Phase: Phase 2
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)
Enrollment Status: Completed
Publish Date: March 20, 2026
Intervention Type: Other, Biological
Study of Anti-Malarials in Incomplete Lupus Erythematosus
Study of Anti-Malarials in Incomplete Lupus Erythematosus
Enrollment Status: Completed
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: Hydroxychloroquine
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Enrollment Status: Completed
Publish Date: October 30, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: August 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
Nelfinavir in Systemic Lupus Erythematosus: A Pilot Phase IIa Clinical Trial
Nelfinavir in Systemic Lupus Erythematosus: A Pilot Phase IIa Clinical Trial
Enrollment Status: Terminated
Publish Date: February 24, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: November 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

249 Total Publications

Clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products: a systematic evaluation.
Clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products: a systematic evaluation.
Journal: Lupus science & medicine
Published: February 06, 2026
Similar Doctors
Expertise in
8
conditions
Expertise in
8
conditions
Referral may be required

Office

1000 Veteran Ave Rm 32-59, 
Los Angeles, CA 
 (3.6 miles away)
310-206-5366
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Christina Charles-Schoeman, MD is a Rheumatology Specialist in Los Angeles, CA. Dr. Charles-Schoeman has extensive experience in Rheumatologic Muscular Diseases and Osteoporosis & Screening. She is affiliated with Ronald Reagan UCLA Medical Center. Dr. Charles-Schoeman is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Dermatomyositis, Polymyositis, Myositis, and Rheumatoid Arthritis (RA). Dr. Charles-Schoeman is board certified in Rheumatology, American Board Of Internal Medicine, 2005.

Expertise in
7
conditions
Dr. Francesco Boin
Rheumatology
Expertise in
7
conditions
Dr. Francesco Boin
Rheumatology
Referral may be required
Before you request

Cedars-Sinai Rheumatology-Los Angeles

8723 Alden Dr Ste 250, 
Los Angeles, CA 
 (0.1 miles away)
310-423-6257
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Francesco Boin is a Rheumatologist practicing medicine in Los Angeles, California. Dr. Boin is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Raynaud Phenomenon. Dr. Boin is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral required
Before you request

Cedars-Sinai Rheumatology-Los Angeles

8723 Alden Dr Ste 250, 
Los Angeles, CA 
 (0.1 miles away)
310-423-6257
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mariko Ishimori is a Rheumatologist practicing medicine in Los Angeles, California. Dr. Ishimori is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Ankylosing Spondylitis, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), and Rheumatoid Arthritis (RA). Dr. Ishimori is currently accepting new patients.

Expertise in
7
conditions
Dr. Jon T. Giles
Rheumatology
Expertise in
7
conditions
Dr. Jon T. Giles
Rheumatology
Referral may be required
Before you request

Cedars-Sinai Rheumatology-Los Angeles

8723 Alden Dr Ste 250, 
Los Angeles, CA 
 (0.1 miles away)
310-423-6257
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jon Giles is a Rheumatologist practicing medicine in Los Angeles, California. Dr. Giles is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Rheumatoid Lung Disease, Hip Replacement, and Knee Replacement. Dr. Giles is currently accepting new patients.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
Before you request

Ronald Reagan UCLA Medical Center

757 Westwood Plz, 
Los Angeles, CA 
 (4.2 miles away)
310-267-9643
Experience:
18+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Volkmann is a Rheumatologist practicing medicine in Los Angeles, California. She has been practicing medicine for over 18 years. Dr. Volkmann is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Scleroma, and Sarcoidosis. Dr. Volkmann is currently accepting new patients.

Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required
Before you request

Henry A Horton MD Inc

8640 W 3rd St Ste 300, 
Los Angeles, CA 
 (0.1 miles away)
800-500-2397
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arash Horizon is a Rheumatologist practicing medicine in Los Angeles, California. Dr. Horizon is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Psoriatic Arthritis, Rheumatoid Arthritis (RA), Psoriasis, and Rheumatoid Lung Disease. Dr. Horizon is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel J. Wallace

How do I make an appointment with Dr. Daniel J. Wallace?

You can book an appointment with Dr. Daniel J. Wallace by calling their office at 310-652-0920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel J. Wallace a top-rated expert for Systemic Lupus Erythematosus (SLE)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel J. Wallace is classified as an Elite expert for Systemic Lupus Erythematosus (SLE), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel J. Wallace specialize in?

While Dr. Daniel J. Wallace is a Rheumatology, they have specific expertise in Systemic Lupus Erythematosus (SLE), Lupus Nephritis, and Sjogren Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Daniel J. Wallace participate in research or clinical trials?

Yes. Dr. Daniel J. Wallace has published 249 articles and abstracts on conditions like Systemic Lupus Erythematosus (SLE). You can view a list of Dr. Daniel J. Wallace's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel J. Wallace accept my insurance?

Dr. Daniel J. Wallace accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-652-0920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wallace's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 12 Advanced Conditions
View All 32 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile